FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
If approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7.
FDX Recognized by CFPB as a Standard-Setting Body, a Step Forward for Open Banking
The Financial Data Exchange (FDX) is pleased to announce its official recognition by the Consumer Financial Protection Bureau (CFPB) as an industry standard-setting body for the U.S. open banking ...